Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

WuXi XDC Cayman Inc(2268 HK)

$71.30+2.403.48%(Market Closed · 08:08:08 UTC · (15 min delay))

Overview

Profile

Financials & Metrics

FinancialsChartingEmployees
Logo
2268 HK​

WuXi XDC Cayman Inc — Company Profile

WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
HK
CEO
Jincai Li
Headquarters
Wuxi, JS, CN
IPO Date
Nov 17, 2023
Employees
2,662
Website
wuxixdc.com

Key Metrics

Price
$81.15
Market Cap
$102.77B
Revenue (TTM)
$3.65B
Net Income (TTM)
$806.71M
EPS (TTM)
0.64
P/E (TTM)
0.00
P/B (TTM)
9.10
Dividend Yield
0.00%
ROE (TTM)
13.80%
ROA (TTM)
10.25%
Operating Margin
27.26%
Beta
0.21

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.

Website
wuxixdc.com
Location
Wuxi, JS, CN
Phone+86 510 8538 5225
Employees2,662
CEOJincai Li
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateNov 17, 2023

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Key Stats

Trading

Px/Chg 1D$81.15 / +0.68%
Avg Volume4.90M
Beta0.21
Mkt Cap102.77B
FD Mkt Cap92.95B

Float

Shrs Out/Float1.27B / 389.94M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$0.00

Current Valuation

EV101.97B
EV/EBITDA0.00
EV/Sales0.00
P/B9.10
P/S0.00
FCF Yield0.61%
ROE13.80%
ROA10.25%
Current Ratio2.68

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgJun '24Jun '25Jun '26Oct '26
PRICE-BASED RATIOS
Price / Earnings84.6666.5444.71100.00127.39
Price / Sales17.878.8811.8022.6528.15
Price / Book Value6.653.467.206.859.10
Price / Free Cash Flow31.97-91.36-60.69116.71163.23
ENTERPRISE VALUE METRICS
Enterprise Value59,006.514,821.446,389.272,846.0101,969.3
Enterprise Value / Sales17.216.9811.4522.4627.93
Enterprise Value / EBITDA58.7335.2734.7978.3386.55
Enterprise Value / EBIT65.1140.5537.9385.3296.65

Financials

Full Financials
Millions CNY5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue109.1%311.1990.42,123.84,052.35,944.2
Gross Income108.4%113.5261.1559.61,239.82,139.3
EBITDA118.6%77.4151.7420.31,333.41,766.1
EBIT128.7%59.2125.9365.51,223.01,620.7
Net Income127.9%54.9155.7283.51,069.61,480.5
EPS (Diluted)121.4%0.050.130.260.831.12
BALANCE SHEET
Cash & ST Inv310.4%26.3735.04,047.63,973.37,467.6
Total Assets101.3%879.82,496.46,735.39,124.114,441.4
Total Liabilities44.2%858.91,015.61,281.02,484.63,711.3
Total Shareholder Equity376.1%20.91,480.85,454.36,639.510,730.1
CASH FLOW
Net Operating Cash Flow136.4%59.1251.8332.8717.21,847.8
Cap Ex119.9%-51.9-201.4-539.4-1,505.2-1,213.2
Free Cash Flow206.1%7.250.4-206.5-788.0634.6

Enterprise Value Bridge

Millions CNY23 Oct '26
Price (As of 23 Oct '26)67.50
Basic Shares1,266.36
Market Cap85,479.6
Diluted Shares1,369.63
Fully Diluted Shares Outstanding1,369.63
Fully Diluted Market Cap92,450.0
+Consolidated Debt531.4
−In-the-Money Convertible Debt—
+Capital Leases32.9
+Operating Leases—
−Cash & Equivalents-1,603.6
−Short-term Investments-4,123.1
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest276.0
+Pension Liabilities—
Enterprise Value84,683.5

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US

DiaSorin S.p.A.

DSRLF US